Molecular Characteristics Molecular Type: Synthetic pentadecapeptide research compound Structure: Linear peptide chain (15 amino acids) Stability: High when stored under recommended laboratory conditions Molecular Weight: Sequence-dependent Molecular Stability and Storage Profile Supplied as a lyophilized powder for enhanced long-term stability Long-term storage: Store at 20C to preserve molecular integrity Sensitive to moisture and prolonged light exposure Predictable degradation above room temperature Reconstituted solutions remain stable for approximately 2448 hours under refrigeration Solubility and Reconstitution Characteristics Bacteriostatic water Sterile saline Acidic buffers Compatible analytical-grade organic solvents Technical Specifications product Name BPC-157 10mg cas 137525-51-0 purity 99% (HPLC verified) unit Size 10 mg vial form Lyophilized powder synthesis Solid-Phase Peptide Synthesis (SPPS) analytical HPLC, Mass Spectrometry, UV Spectrophotometry molecular Structure Linear peptide chain stability High when stored under recommended conditions Analytical Validation and Quality Assurance High-Performance Liquid Chromatography (HPLC) purity confirmation Mass Spectrometry (MS) molecular identity and sequence verification UV spectrophotometric concentration analysis Batch identity and consistency verification Endotoxin and microbial contamination screening Regulatory and Compliance Statement BPC-157 10mg is supplied strictly for laboratory research and scientific investigation

Oral supplementation is usually sufficient for individuals with mild to moderate deficiency due to dietary insufficiency or malabsorption disorders
Patients may read about thymosin beta-4 wound-healing studies and assume the same conclusions apply directly to commercially marketed TB-500 products
Understanding This Powerful Healing Peptide If you're recovering from an injury, dealing with chronic joint pain, or looking for a way to accelerate healing after surgery, you may have heard about BPC-157
Conditions in which BPC-157 dosage for dogs by weight might not be prescribed
If reticulocytes have not increased after treatment or if reticulocyte counts do not continue at least twice normal as long as the hematocrit is less than 35%, diagnosis or treatment should be reevaluated